Topic

Articles

Teva Pharmaceuticals and Neos Therapeutics entered into a settlement and licensing agreement to resolve all ongoing litigation involving Neos' patents protecting its Cotempla (methylphenidate) extended-release orally disintegrating tablets.

Neos Therapeutics, Teva Settle on Patent Litigation for ADHD Drug

AbbVie will grant Pfizer license to launch a biosimilar to AbbVie’s Humira worldwide.

Pfizer Gets Global Patent License for AbbVie’s Humira

AbbVie will grant Momenta license to launch a biosimilar to AbbVie’s Humira.

AbbVie Signs Patent License with Momenta for Humira Biosimilar

Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab). 

Sandoz Humira Biosimilar Patent Dispute Resolved

Agnes Shanley is senior editor of Pharmaceutical Technology.

Biotechnology developers should be aware of subtle differences between the way that European and United States patent authorities approach monoclonal antibodies.

Protecting Antibody IP: Consider Regional Differences

The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development.

A-Alpha Bio Wins NSF Grant for Cancer Drug Development

Waters’ acquisition of Prosolia’s DESI technology boosts its mass spectrometry imaging portfolio.

Waters Acquires Mass Spec Technology

AbbVie will grant Mylan license to launch a biosimilar to AbbVie’s Humira.

AbbVie Signs Patent License with Mylan for Humira Biosimilar

Shashank Upadhye, Esq., managing partner at Amin Talati Upadhye, will discuss intellectual property/patent issues for active pharmaceutical ingredients and abbreviated new drug applications at CPhI North America in Philadelphia, PA, on Tuesday, April 24, 2018.

Insight Briefing on IP/Patent Issues for API and ANDA Applicants

Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.

Intellectual Property & Patents